Effects of CYP2C19 variants on the metabolism of tapentadol in vitro

被引:1
|
作者
Xu, Ren-ai [1 ]
Fang, Ping [2 ]
Ye, Zhize [3 ]
Han, Mingming [3 ]
Cai, Jian-Ping [4 ]
Hu, Guo-Xin [3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China
[4] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol,Natl Hlth Commiss, Key Lab Geriatr,Beijing Inst Geriatr,Inst Geriatr, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
Cytochrome P450; Drug metabolism; Genetic polymorphism; Tapentadol; FUNCTIONAL-CHARACTERIZATION; GENETIC-POLYMORPHISM; ALLELIC VARIANTS; PHARMACOLOGY; POPULATION; TRAMADOL; ENZYMES; 2C19;
D O I
10.22038/IJBMS.2022.56996.12710
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective(s): This study aims to evaluate the catalytic activities of 31 CYP2C19 alleles and their effects on the metabolism of tapentadol in vitro. Materials and Methods: Insect microsomes expressing the CYP2C19 alleles were incubated with 50- 1250 mu M tapentadol for 40 min at 37 degrees C and terminated by cooling to -80 degrees C, immediately. Tapentadol and N-desmethyl tapentadol were analyzed by a UPLC-MS/MS system. The kinetic parameters Km, Vmax, and intrinsic clearance (Vmax/Km) of N-desmethyl tapentadol were determined. Results: As a result, the intrinsic clearance (Vmax/Km) values of most variants were significantly altered, while CYP2C19.3 and 35FS had no detectable enzyme activity. Only one variant, N277K, showed no significant difference from CYP2C19.1B. Two variants CYP2C19.29 and L16F displayed markedly increased intrinsic clearance values of 302.22% and 199.97%, respectively; whereas 24 variants exhibited significantly decreased relative clearance ranging from 0.32% to 79.15% of CYP2C19.1B. Especially, CYP2C19.2G, 2H, R124Q, and R261W exhibited a drastic decrease in clearance (>80%) compared with wild-type CYP2C19.1B. Conclusion: As the first study of all aforementioned alleles for tapentadol metabolism, the comprehensive data in vitro may provide novel insights into the allele-specific and substrate-specific activity of CYP2C19.
引用
收藏
页码:659 / 663
页数:5
相关论文
共 50 条
  • [41] Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
    Nastasi-Catanese, J. A.
    Padilla-Gutierrez, J. R.
    Valle, Y.
    Ortega-Gutierrez, F.
    Gallegos-Arreola, M. P.
    Figuera, L. E.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (04) : 4413 - 4421
  • [42] Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy
    Tantray, Javeed Ahmad
    Reddy, K. Pratap
    Jamil, Kaiser
    Kumar, Y. Shiva
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 229 : 113 - 118
  • [43] CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
    Damkier, Per
    Kjaersgaard, Anders
    Barker, Kimberly A.
    Cronin-Fenton, Deidre
    Crawford, Anatasha
    Hellberg, Ylva
    Janssen, Emilius A. M.
    Langefeld, Carl
    Ahern, Thomas P.
    Lash, Timothy L.
    SCIENTIFIC REPORTS, 2017, 7
  • [44] Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru
    Alvarado, Angel
    Munoz, Ana Maria
    Varela, Nelson
    Sullon-Dextre, Luis
    Pineda, Mario
    Bolarte-Arteaga, Mario
    Bendezu, Maria R.
    Garcia, Jorge A.
    Chavez, Haydee
    Surco-Laos, Felipe
    Melgar-Merino, Elizabeth J.
    Cuba-Garcia, Pompeyo A.
    Molina-Cabrera, Aura
    Pari-Olarte, Bertha
    Bonifaz-Hernandez, Mario
    Panay-Centeno, Juan F.
    Kong-Chirinos, Jose
    Almeida-Galindo, Jose
    PHARMACIA, 2023, 70 (03) : 603 - 618
  • [45] SCREENING FOR CYP2C19*2, *3 AND *4 GENE VARIANTS IN A ROMANIAN POPULATION STUDY GROUP
    Buzoianu, Anca D.
    Trifa, Adrian P.
    Popp, Radu A.
    Militaru, Mariela S.
    Militaru, Claudia F.
    Bocsan, Corina I.
    Farcas, Marius F.
    Pop, Ioan V.
    FARMACIA, 2010, 58 (06) : 806 - 817
  • [46] Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients
    Jaja, Cheedy
    Barrett, Nadine
    Patel, Niren
    Lyon, Matt
    Xu, Hongyan
    Kutlar, Abdullah
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2016, 20 (10) : 609 - 615
  • [47] In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5
    Agbokponto, Janvier Engelbert
    Zhang, Lingling
    Hu, Linlin
    Feng, Hao
    Ding, Li
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (01) : 69 - 77
  • [48] In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5
    Janvier Engelbert Agbokponto
    Lingling Zhang
    Linlin Hu
    Hao Feng
    Li Ding
    European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 69 - 77
  • [49] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
  • [50] Effect of CYP2D6 variants on venlafaxine metabolism in vitro
    Zhan, Yun-Yun
    Liang, Bing-Qing
    Wang, Hao
    Wang, Zhen-He
    Weng, Qing-Hua
    Dai, Da-Peng
    Cai, Jian-Ping
    Hu, Guo-Xin
    XENOBIOTICA, 2016, 46 (05) : 424 - 429